STOCK MARKET BSE NSE

Human trials of Covid vaccine at Andhra Medical College soon

The Pune-based Serum Institute of India (SII) has partnered with British-Swedish pharmaceutical company AstraZeneca to manufacture the Covid-19 vaccine in India. 

Published: 24th September 2020 09:35 AM  |   Last Updated: 24th September 2020 10:14 AM   |  A+A-

Lab, test, In this handout photo released by the University of Oxford samples from vaccine trials are handled inside the Oxford Vaccine Group laboratory.

Image used for representational purpose only. (Photo | AP)

By Express News Service

VISAKHAPATNAM: Andhra Medical College-King George Hospital has been geared up to conduct the third phase of human trials of coronavirus vaccine Covishield, developed jointly by University of Oxford’s Jenner Institute and AstraZeneca. The Pune-based Serum Institute of India (SII) has partnered with British-Swedish pharmaceutical company AstraZeneca to manufacture the Covid-19 vaccine in India. 

A team of SII conducted virtual inspection of facilities and equipment at Andhra Medical College, said Dr PV Sudhakar, AMC principal and co-investigator of vaccine trials. Following the approval of Drug Controller General of India (DCGI), the final stage of clinical trials of Covid-19 vaccine candidates began in Pune and Mumbai. Trials will begin at AMC-KGH soon.

Dr Sudhakar said a 20-member team, including principal investigator B Devi Madhavi, and six co-investigators, was formed for conducting the clinical trials. A training and awareness programme for the team was conducted. 

The clinical trials will be conducted as per the ICMR protocol. A two-bed ward has been ready at the AMC for conducting the trials. About 100 volunteers in the age group of 18 to 60 years will be chosen for the trials. Volunteers need to test negative in both RT PCR and antigen tests and they should not have any comorbidities. The vaccine will be administered to three to four volunteers a day. 

The process will begin once they get the vaccine and drug from SII. The investigators will not know which one contains the drug or vaccine, Dr Sudhakar said. 

He said AMC-KGH was chosen for the clinical trials of Covishield  based on its track record of conducting trials for the vaccine for dengue and measles in the past. Volunteers will be in observation at the hospital for two to three hours and later they will be allowed to go home. The need to visit the hospital if they develop any problem. Hospital PROs will monitor the health status of the volunteers on a regular basis by contacting them over phone. 



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp